First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers
- 11 January 2010
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 30 (3) , 235-240
- https://doi.org/10.1002/pd.2445
Abstract
Objective: To assess the impact of a vanishing twin on the levels of the biochemical markers used in the first trimester aneuploidy screening.Methods: A retrospective analysis of free β‐hCG and PAPP‐A levels in 270 women with a normal singleton fetus with ultrasound evidence of a vanishing twin pregnancy. Marker levels (as MoM) were compared in three groups—76 women with a second empty gestational sac, 194 women with a second gestational sac containing a dead fetus with a measurable crown rump length (CRL), and 1360 matched singleton pregnancies.Results: In women with a second empty gestational sac, the median free β‐hCG and PAPP‐A MoMs (0.968 and 1.040, respectively) were not significantly different from the 1.0 MoM in singleton pregnancies. In the group with a vanished twin with a measurable—CRL—there was a significantly increased median PAPP‐A MoM (1.317) but the median free β‐hCG MoM was not changed (1.024). Modelling this bias in PAPP‐A MoM the detection rate for trisomy 21 would fall from 85 to 75%.Conclusion: First trimester screening in the presence of a vanishing twin may lead to errors in risk estimation. In such circumstances it may be advisable to restrict screening to the use of nuchal translucency (NT) alone. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 41 references indexed in Scilit:
- Maternal serum screening marker levels in women with a previous aneuploidy pregnancyPrenatal Diagnosis, 2009
- Down syndrome screening marker levels in women with a previous aneuploidy pregnancyPrenatal Diagnosis, 2005
- Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisitedPrenatal Diagnosis, 2002
- The influence of parity and gravidity on first trimester markers of chromosomal abnormalityPrenatal Diagnosis, 2000
- The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Screening for triploidy by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Screening for trisomy 21 in twin pregnancies in the first trimester using free ?-hCG and PAPP-A, combined with fetal nuchal translucency thicknessPrenatal Diagnosis, 2000
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999
- Metabolic and renal clearance rates of purified human chorionic gonadotropin.Journal of Clinical Investigation, 1981